Авторы
Гительзон Е.А.1, Файбушевич А.Г.1, Гительзон Д.Г.1, 2, Веретник Г.И.1
1 ФГАОУ «Российский университет дружбы народов», Москва
2 ФГБУ «НМИЦ гематологии», Москва
Аннотация
Усовершенствование диагностических и лечебных схем для больных гемобластозами позволило повысить уровень выживаемости среди этих пациентов. Однако в клинической практике наблюдается тенденция к увеличению количества пациентов с сочетанием ИБС и гемобластоза. В большинстве случаев наличие конкурирующей ИБС у онкогематологических больных осложняет лечение основного заболевания. Кардиотоксичность химиотерапии может стать потенциальной причиной прерывания или прекращения противоопухолевого лечения, потенциально ухудшая «общий» прогноз жизни. До сих пор нет ясности по проведению чрескожных коронарных вмешательств у больных гемобластозами, так в литературе представлены лишь отдельные описания случаев.
Ключевые слова: ишемическая болезнь сердца, гемобластоз, чрескожное коронарное вмешательство.
Список литературы
1. Березин П.Г., Милованов В.В., Иванников А.А. Роль эритропоэтинов в лечении анемии у онкологических больных // Исследования и практика в медицине. — 2017. — Т.4. — №2. — С. 37–42. doi: 10.17709/2409-2231-2017-4-2-5.
2. Владимирова С.Г., Тарасова Л.Н., Скольская О.Ю. Показатели гемостаза у больных острым миелоидным лейкозом в период манифестации заболевания // Онкогематология. — 2012. — Т.7. — №2. — С. 36–41. doi: 10.17650/1818-8346-2012-7-2-36-41.
3. Голубцов О.Ю., Тыренко В.В., Лютов В.В. и др. Кардиоваскулярные осложнения противоопухолевой терапии // Современные проблемы науки и образования. — 2017. — №2. — С. 1–15. URL.
4. Емелина Е.И., Шуйкова К.В., Гендлин Г.Е. и др. Поражение сердца при лечении современными противоопухолевыми препаратами и лучевые повреждения сердца у больных с лимфомами // Клиническая онкогематология. — 2009. — Т.2. — №2. — С. 152–160. URL.
5. Коколис С., Тарко Д.Б., Меран Р. и др. Системная химиотерапия сопутствующих раковых образований снижает частоту рестенозов после стентирования коронарных артерий // Международный журнал интервенционной кардиоангиологии. — 2003. — №3. — С. 26–29.
6. Кольцова Е.М., Баландина А.Н., Серегина Е.А., и др. Аспекты методологии лабораторных исследований гемостаза в детской гематологии-онкологии и общие подходы в патологии гемостаза при лейкозах // Российский журнал детской гематологии и онкологии. — 2018. — Т.5. — №3. — С. 74–88. doi:10.17650/2311-1267-2018-5-3-74-88.
7. Прус Ю.А., Сергиенко И.В., Кухарчук В.В. и др. Кардиотоксичность, индуцированная химиотерапией и лучевой терапией // Атеросклероз и дислипидемии. — 2017. — Т.3. — №28. — С. 56–72.
8. Селиверстова Д.В., Евсина О.В. Кардиотоксичность химиотерапии // Сердце: журнал для практикующих врачей. — 2016. — Т.15. — №1. — С. 50–57. doi: 10.18087/rhj.2016.1.2115.
9. Aleman BMP, Belt-Dusebout AWVD, Bruin MLD, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007; 109(5): 1878–1886. doi: 10.1182/blood-2006-07-034405.
10. Ariotti S, Adamo M, Costa F, et al. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention? J Am Coll Cardiol Intv. 2016; 9(5): 426–436. doi: 10.1016/j.jcin.2015.11.015.
11. Arunprasath P, Gobu P, Dubashi B, et al. Rituximab induced myocardial infarction: a fatal drug reaction J. Cancer Res. Ther. 2011; 7(3): 346–348. doi: 10.4103/0973-1482.87003.
12. Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract. 2011; 11: 394740. doi: 10.4061/2011/394740.
13. Bromberg ME, Cappello M. Cancer and blood coagulation: molecular aspects. Cancer J. Sci. Am. 1999; 5(3): 132–138. URL.
14. Cesarman-Maus G, Braggio E, Fonseca R. Thrombosis in multiple myeloma (MM). Hematology. 2012; 17(1): 177–180. doi: 10.1179/102453312X13336169156933.
15. Cheng H, Feldman T, Butt Y, et al. T-cell prolymphocytic leukemia with extensive cardiovascular infiltrate leading to multiple myocardial infarctions and cardiac death. Tex. Heart Inst. J. 2014; 41(6): 626–630. doi: 10.14503/THIJ-13-3581.
16. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012; 23(7): 155–66. doi: 10.1093/annonc/mds293.
17. Darby SC, Ewertz M, McGalle P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013; 368(11): 987–998. doi: 10.1056/NEJMoa1209825.
18. Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A. 2012; 109(32): 13076–13081. doi: 10.1073/pnas.1200419109.
19. Desai MY, Jellis CL, Kotecha R, et al. Radiation-Associated Cardiac Disease: A Practical Approach to Diagnosis and Management. JACC: Cardiovascular Imaging. 2018; 11(8): 1132–1149. doi: 10.1016/j.jcmg.2018.04.028.
20. Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001; 19(4): 1137–1146. doi: 10.1200/JCO.2001.19.4.1137.
21. Falanga A, Russo L, Milesi V. The coagulopathy of cancer. Curr Opin Hematol. 2014; 21(5): 423–429. doi: 10.1097/MOH.0000000000000072.
22. Ganatra S, Sharma A, Levy MS. Re-evaluating the safety of drug-eluting stents in cancer patients. JACC Cardiovasc Interv. 2017; 10(22): 2334–2337. doi:10.1016/j.jcin.2017.06.068.
23. Garot P, Morice MC, Tresukosol D, et al. 2-year outcomes of high bleeding risk patients after polymer-free drug-coated stents. J Am Coll Cardiol. 2017; 69(2): 162–171. doi: 10.1016/j.jacc.2016.10.009.
24. Giza DE, Iliescu G, Hassan S, et al. Cancer as a risk factor for cardiovascular disease. Curr Oncol Rep. 2017; 19(6): 39. doi: 10.1007/s11912-017-0601-x.
25. Goad KE, Gralnick HR. Coagulation disorders in cancer. Hematol Oncol Clin North Am. 1996; 10(2): 457–484. doi: 10.1016/s0889-8588(05)70347-6.
26. Hancock SL, Tucker MA, Hoppe RT. Factors Affecting Late Mortality from Heart Disease after Treatment of Hodgkin’s Disease. JAMA. 1993; 270(16): 1949–1955. URL.
27. Hendry JH. Threshold doses and circulatory disease risks. Ann ICRP. 2015; 44 (Suppl 1): 69–75. doi: 10.1177/0146645314560688.
28. Herrmann J, Lerman A, Sandhu NP, et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014; 89(9): 1287–1306. doi:10.1016/j.mayocp.2014.05.013.
29. Hillen HF. Thrombosis in cancer patients. Ann. Oncol. 2000; 11(3): 273–276. doi: 10.1093/annonc/11.suppl_3.273.
30. Iliescu CA, Grines CL, Herrmann J, et al. SCAI Expert Consensus Statement: Evaluation, Managment, and Special Considerations of Cardio-Oncology Patients in the Cardiac Catheterization Laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiolog a Intervencionista). Catheter Cardiovasc Interv. 2016; 87(5): 202–223. doi: 10.1002/ccd.26379.
31. Jao GT. ST-elevation myocardial infarction and myelodysplastic syndrome with acute myeloid leukemia transformation. Tex Heart Inst J. 2014; 41(2): 234–237. Published 2014 Apr 1. doi:10.14503/THIJ-12-2905.
32. Johnson CB, Davis MK, Law A, et al. Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients. Can J Cardiol. 2016; 32(7): 900–907. doi: 10.1016/j.cjca.2016.04.008.
33. Khosrow-Khavar F, Filion KB, Al-Qurashi S, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2017; 28(3): 487–496. doi: 10.1093/annonc/mdw673.
34. Koene RJ, Prizment AE, Blaes A, et al. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016; 133(11): 1104–1114. doi: 10.1161/CIRCULATIONAHA.115.020406.
35. Kolh P, Windecker S, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014; 46(4): 517–592. doi: 10.1093/ejcts/ezu366.
36. Koltowski L, Tomaniak M, Aradi D, et al. Optimal aNtiplate-let pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective PCI patients: A pilot study: ONSIDE TEST pilot. Cardiol J. 2017; 24(3): 284–292. doi: 10.5603/CJ.a2017.0026.
37. Kroll MH, Feng S. Targeting shear stress-induced platelet activation: is lesion-specific antiplatelet therapy a realistic clinical goal? Expert Rev Cardiovasc Ther. 2005; 3(5): 941–951. doi: 10.1586/14779072.3.5.941.
38. Kwok CS, Khan MA, Rao CV, et al. Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis. Circ Cardiovasc Interv. 2015; 8(4): 001645. doi: 10.1161/CIRCINTERVENTIONS.114.001645.
39. Kwok CS, Rao SV, Myint PK, et al. Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis. Open Heart. 2014; 1(1): 000021. doi: 10.1136/openhrt-2013-000021.
40. Lancellotti P, Nkomo VT, Badano LP, et al. Expert Consensus for Multi-Modality Imaging Evaluation of Cardiovascular Complications of Radiotherapy in Adults: A Report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Journal of the American Society of Echocardiography. 2013; 28(9): 1013–1032. doi: 10.1016/j.echo.2013.07.005.
41. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/ /SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/ AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Car-diovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016; 134(10): 123–155. doi: 10.1161/CIR.0000000000000404.
42. Liang JJ, Sio TT, Slusser JP, et al. Outcomes after percutaneous coronary intervention with stents in patients treated with thoracic external beam radiation for cancer. J Am Coll Cardiol Intv. 2014; 7(12): 1412–1420. doi: 10.1016/j.jcin.2014.05.035.
43. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420(6917): 868–874. doi: 10.1038/nature01323.
44. Liu VY, Agha AM, Lopez-Mattei J, et al. Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field. Front Cardiovasc Med. 2018; 5: 48. doi: 10.3389/fcvm.2018.00048.
45. Mandel EM, Lewinski U, Djaldetti M. Vincristine-induced myocardial infarction. Cancer. 1975; 36(6): 1979–1982. doi: 10.1002/cncr.2820360908.
46. Mercadante S, Gebbia V, Marrazzo A, et al. Anemia in cancer: pathophysiology and treatment. Cancer Treat Rev. 2000; 26(4): 303–311. doi: 10.1053/ctrv.2000.0181.
47. Meredith IT, Verheye S, Dubois C, et al. Final five-year clinical outcomes in the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. Eurointervention. 2018; 13(17): 2047–2050. doi: 10.4244/EIJ-D-17-00529.
48. Mohanty BD, Mohanty S, Hussain Y, et al. Management of ischemic coronary disease in patients receiving chemotherapy: an uncharted clinical challenge. Future Cardio. 2017; 13(3): 247–257. doi:10.2217/fca-2017-0002.
49. Odell TT, Murphy JR, Jackson CW. Stimulation of megakaryocytopoiesis by acute thrombocytopenia in rats. Blood. 1976; 48(5): 765–775. URL.
50. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Am Soc Echocardiogr. 2014; 27(9): 911–939. doi: 10.1016/j.echo.2014.07.012.
51. Polk A, Vistisen K, Vaage-Nilsen M, et al. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014; 15: 47. doi: 10.1186/2050-6511-15-47.
52. Potts J, Mohamed MO, Lopez Mattei JC, et al. Percutaneous coronary intervention and in-hospital outcomes in patients with leukemia: a nationwide analysis. Catheter Cardiovasc Interv. 2020; 96(1): 53–63. doi: 10.1002/ccd.28432.
53. Renard D, Cornillet L, Castelnovo G. Myocardial infarction after rituximab infusion. Neuromuscul Disord. 2013; 23(7): 599–601. doi: 10.1016/j.nmd.2013.03.014.
54. Roy A, Khanna N, Senguttuvan NB. Rituximab-vincristine chemotherapy-induced acute anterior wall myocardial infarction with cardiogenic shock. Tex Heart Inst J. 2014; 41(1): 80–82. doi: 10.14503/THIJ-12-2853.
55. Saiki H, Petersen IA, Scott CG, et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation. 2017; 135(15): 1388–1396. doi: 10.1161/CIRCULATIONAHA.116.025434
56. Schomig K, Ndrepepa G, Mehilli J, et al. Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement. Catheter Cardiovasc Interv. 2007; 70(3): 359–365. doi: 10.1002/ccd.21109.
57. Siller-Matula JM, Trenk D, Schrör K, et al. Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv. 2013; 6(11): 1111–1128. doi: 10.1016/j.jcin.2013.06.011.
58. Sofi F, Giusti B, Marcucci R, et al. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. 2011; 11(3): 199–206. doi: 10.1038/tpj.2010.21.
59. Stefenelli T, Kuzmits R, Ulrich W, et al. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J. 1988; 9(5): 552–556. doi: 10.1093/oxfordjournals.eurheartj.a062542.
60. Stewart FA. Mechanisms and dose-response relationships for radiation-induced cardiovascular disease. Ann ICRP. 2012; 41(3–4): 72–79. doi: 10.1016/j.icrp.2012.06.031.
61. Stewart FA, Seemann I, Hoving S, et al. Understanding radiation-induced cardiovascular damage and strategies for intervention. Clin Oncol. 2013; 25(10): 617–624. doi: 10.1016/j.clon.2013.06.012.
62. Stewart FA, Hoving S, Russell NS. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients. Radiat Res. 2010; 174(6): 865–869. doi: 10.1667/RR1862.1.
63. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart Jn. 2013; 34(15): 1102–1111. doi:10.1093/eurheartj/ehs181.
64. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013; 62(24): 2261–2273. doi: 10.1016/j.jacc.2013.07.101.
65. Totzeck M, Schuler M, Stuschke M, et al. Cardio-oncology — strategies for management of cancer-therapy related cardiovascular disease. International Journal of Cardiology. 2019; 280: 163–175. doi: 10.1016/j.ijcard.2019.01.038.
66. Wang F, Gulati R, Lennon RG, et al. Cancer history portends worse acute and long-term noncardia (but not cardiac) mortality after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Mayo Clin Proc. 2016; 91(12): 1680–1692. doi: 10.1016/j.mayocp.2016.06.029.
67. Weaver KE, Foraker RE, Alfano CM, et al. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? J Cancer Surviv. 2013; 7(2): 253–261. doi: 10.1007/s11764-013-0267-9.
68. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009; 53(24): 2231–2247. doi: 10.1016/j.jacc.2009.02.050.
69. Yusuf SW, Iliescu C, Bathina JD, et al. Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. Tex Heart Inst J. 2010; 37(3): 336–340. URL.
70. Zamorano JL, Lancellotti P, Munoz DR, et al. ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(36): 2768–2801. doi: 10.1093/eurheartj/ehw211.
